Neurocrine Biosciences, Inc.
NBIXNext catalyst
Valbenazine Oral Capsule
Trichotillomania (Hair-Pulling Disorder)
Get an email about NBIX's next catalysts
Track Neurocrine Biosciences (NBIX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 4 more upcoming events in our data (Phase 2 readout, Phase 3 readout).See the timeline
5 upcoming, 2 past
Valbenazine Oral Capsule Phase 2 Est. Readout
Estimated primary completion for Valbenazine Oral Capsule trial (NCT05207085) in Trichotillomania (Hair-Pulling Disorder). Topline data typically follows completion by weeks to months.
SourceNBI-1065890 Phase 2 Est. Readout
Estimated primary completion for NBI-1065890 trial (NCT07365462) in Tardive Dyskinesia. Topline data typically follows completion by weeks to months.
SourceNBI-1065845 Phase 3 Est. Readout
Primary completion for NBI-1065845 trial (NCT06963021) in Major Depressive Disorder
SourceNBI-1117570 Phase 2 Est. Readout
Estimated primary completion for NBI-1117570 trial (NCT07288333) in Schizophrenia. Topline data typically follows completion by weeks to months.
SourceNBI-1117568 Phase 3 Est. Readout
Primary completion for NBI-1117568 trial (NCT06963034) in Schizophrenia
SourceMarket Overview
Stock performance and key metrics
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
WebsiteChronocort
Congenital Adrenal Hyperplasia
NBI-1065845
Major Depressive Disorder
Infacort®
Adrenal Insufficiency
Crinecerfont
Congenital Adrenal Hyperplasia
Valbenazine
Tardive Dyskinesia
NBI-98854
Tardive Dyskinesia
NBI-1117568
Schizophrenia
Osavampator
Major Depressive Disorder
Chronocort®
Congenital Adrenal Hyperplasia
interleukin-4 PE38KDEL cytotoxin
Brain and Central Nervous System Tumors
NBI-827104
Epileptic Encephalopathy
Plenadren
Primary Adrenal Insufficiency
Cortef
Congenital Adrenal Hyperplasia
NBI-1117570
Schizophrenia
NBI-1065890
Tardive Dyskinesia
Valbenazine Oral Capsule
Trichotillomania (Hair-Pulling Disorder)
Hydrocortisone Modified Release Capsules
Endocrine Disease
Second Generation Antipsychotics (SGA)
Stable Schizophrenia
NBI-921352
SCN8A Developmental and Epileptic Encephalopathy Syndrome
NBI-74788
CAH - Congenital Adrenal Hyperplasia
NBI-1070770
Major Depressive Disorder
TAK-041
Stable Schizophrenia
NBI-5788
Multiple Sclerosis
Luvadaxistat
Schizophrenia
NBI-1065846
Anhedonia
TAK-831
Friedreich Ataxia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Chronocort | Phase 3 | Congenital Adrenal Hyperplasia | - | - |
NBI-1065845 | Phase 3 | Major Depressive Disorder | - | - |
Infacort® | Phase 3 | Adrenal Insufficiency | - | - |
Crinecerfont | Phase 3 | Congenital Adrenal Hyperplasia | - | - |
Valbenazine | Phase 3 | Tardive Dyskinesia | - | - |
NBI-98854 | Phase 3 | Tardive Dyskinesia | - | - |
NBI-1117568 | Phase 3 | Schizophrenia | - | - |
Osavampator | Phase 3 | Major Depressive Disorder | - | - |
Chronocort® | Phase 3 | Congenital Adrenal Hyperplasia | - | - |
interleukin-4 PE38KDEL cytotoxin | Phase 2 | Brain and Central Nervous System Tumors | - | - |
NBI-827104 | Phase 2 | Epileptic Encephalopathy | - | - |
Plenadren | Phase 2 | Primary Adrenal Insufficiency | - | - |
Cortef | Phase 2 | Congenital Adrenal Hyperplasia | - | - |
NBI-1117570 | Phase 2 | Schizophrenia | - | - |
NBI-1065890 | Phase 2 | Tardive Dyskinesia | - | - |
Valbenazine Oral Capsule | Phase 2 | Trichotillomania (Hair-Pulling Disorder) | - | - |
Hydrocortisone Modified Release Capsules | Phase 2 | Endocrine Disease | - | - |
Second Generation Antipsychotics (SGA) | Phase 2 | Stable Schizophrenia | - | - |
NBI-921352 | Phase 2 | SCN8A Developmental and Epileptic Encephalopathy Syndrome | - | - |
NBI-74788 | Phase 2 | CAH - Congenital Adrenal Hyperplasia | - | - |
NBI-1070770 | Phase 2 | Major Depressive Disorder | - | - |
TAK-041 | Phase 2 | Stable Schizophrenia | - | - |
NBI-5788 | Phase 2 | Multiple Sclerosis | - | - |
Luvadaxistat | Phase 2 | Schizophrenia | - | - |
NBI-1065846 | Phase 2 | Anhedonia | - | - |
TAK-831 | Phase 2 | Friedreich Ataxia | - | - |
obesity, metabolic disease
1 drug in this indication
Obesity and metabolic disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Neurocrine Biosciences, Inc.'s drug pipeline?→
CatalystAlert tracks 26 drug candidates in Neurocrine Biosciences, Inc.'s (NBIX) pipeline across Phase 3, Phase 2. Its lead program is NBI-1065845 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Neurocrine Biosciences, Inc.'s next FDA catalyst?→
Neurocrine Biosciences, Inc.'s (NBIX) next tracked catalyst is a Phase 2 readout expected February 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NBIX biotech catalysts?→
Add NBIX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Neurocrine Biosciences, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.